Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Burosumab - Kyowa Hakko Kirin Pharma/Ultragenyx Pharmaceutical

Next Previous
Drug Profile

Burosumab - Kyowa Hakko Kirin Pharma/Ultragenyx Pharmaceutical

Alternative Names: Anti-FGF23 monoclonal antibody; Anti-fibroblast growth factor 23 monoclonal antibody; burosumab-twza; Crysvita; KRN 23; UX 023

Latest Information Update: 26 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko Kirin
  • Developer Kyowa Hakko Kirin; Kyowa Kirin; Ultragenyx Pharmaceutical
  • Class Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Fibroblast growth factor 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - X-linked dominant hypophosphataemic rickets; Osteomalacia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteomalacia; X-linked dominant hypophosphataemic rickets
  • Phase II Nevus

Most Recent Events

  • 27 Sep 2024 Adverse events and efficacy data from a phase III trial in X-linked dominant hypophosphataemic rickets presented at the Annual Meeting of the American Society for Bone and Mineral Research 2024 (ASBMR-2024)
  • 16 Sep 2024 9425186- Observational trial, hence not covered
  • 07 Aug 2024 Kyowa Kirin enters into a distribution agreement with NewBridge Pharmaceuticals to commercialise burosumab in Middle East and North Africa

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top